Evidence map›Paper›PMID 39737595›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2025

The RAB32 p.Ser71Arg Variant in Parkinsonisms: Insights from a Large Italian Cohort.

Luca Magistrelli, Marta Brumana, Valeria Rimoldi, Sofia Poggi-Longostrevi, Elena Contaldi, Gianni Pezzoli, Letizia Straniero, Ioannis U Isaias, Rosanna Asselta

Abstract read
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. RAB32-Linked Parkinson's Disease: Deep Phenotyping, MDSGene Literature Review, and Application of SynNeurGe Criteria.Movement disorders : official journal of the Movement Disorder Society · 2025
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luca MagistrelliASST G. Pini-CTO, Parkinson Institute of Milan, Milan, Italy.ORCID https://orcid.org/0000-0002-9546-8567
Marta BrumanaDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Valeria RimoldiDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Sofia Poggi-LongostreviDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Elena ContaldiASST G. Pini-CTO, Parkinson Institute of Milan, Milan, Italy.ORCID https://orcid.org/0000-0002-0218-5251
Gianni PezzoliASST G. Pini-CTO, Parkinson Institute of Milan, Milan, Italy.
Letizia StranieroDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Ioannis U IsaiasASST G. Pini-CTO, Parkinson Institute of Milan, Milan, Italy.
Rosanna AsseltaDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.ORCID https://orcid.org/0000-0001-5351-0619

Funding

Fondazione Pezzoli per il Morbo di Parkinson
6 · The paper itself

Abstract

BACKGROUND AND

objectiveRecently, RAB32 has been identified as possibly linked to Parkinson's disease. We studied the prevalence and clinical correlates of the p.Ser71Arg variant in the RAB32 gene in a large case series of Italian patients with Parkinson's disease or atypical parkinsonism.

methodsA single-center cohort with a case-control component (consecutively collected at the Parkinson Institute of Milan between 2002 and 2023) was screened for the RAB32 p.Ser71Arg variant. Detailed clinical characteristics of carriers were reviewed. Healthy control subjects were partners or unrelated caregivers. The variant was detected by a TaqMan polymerase chain reaction assay.

resultsA total of 4600 patients (3762 with PD and 838 with atypical parkinsonisms) and 1722 healthy control subjects were consecutively included in the study. We identified 20 new variant carriers that, together with the 8 previously identified, had younger age at onset than noncarriers (51.0 ± 10.7 vs. 58.3 ± 11.0 years, respectively; P = 0.01). All carriers had a good response to dopaminergic therapy and device-aided therapies. Carriers had mild or no cognitive decline and mild or no depressive symptoms; six had impulse control disorders and one a REM behavior disorder. Family history was positive in 55.5% of cases versus 22.0% of patients without the variant (P < 0.001) and was compatible with a dominant pattern of inheritance. The variant was not identified in patients with atypical parkinsonisms.

conclusionsThis study confirms that RAB32 is associated with a relatively young adult-onset PD with a favorable therapeutic response. This variant should be included in genetic panels used for the diagnosis of familial and/or relatively young-onset PD. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

Parkinson DiseaseParkinsonian Disordersrab GTP-Binding ProteinsAdultAgedCase-Control StudiesCohort StudiesFemaleHumansItalyMaleMiddle Agedrab GTP-Binding ProteinsgeneticsParkinson's diseaseRAB32

Identifiers

PMID39737595
PMCPMC11926488

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.